Amarpreet Sawhney, Ph.D., is the Founder, Chief Executive Officer and Chairman of the Board of Directors. Dr. Sawhney served as CEO of Augmenix, an affiliate of Ocular Therapeutix, from 2008 until April 2014. In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of AccessClosure, Inc., acquired by Cardinal Health in 2014. Dr. Sawhney’s innovations are the subject of over 100 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.
Doug Billings has 25 years of experience in innovation, product development and commercialization in medical devices and biopharma. At PRTM/PWC major clients included Boston Scientific, Covidien, Becton Dickinson, CR Bard, Baxter, Phillips, Merck, and Schering Plough. Prior to PRTM, Doug led Business Development and Product Marketing for Organogenesis Inc. He has a MBA and BS in Biology.
VP of R&D
Ray Lareau has over 20 years of experience in research, development, commercialization, and manufacturing of medical devices in array of fields including interventional radiology, endoscopy, urology, oncology, and cardiology. His previous positions were at Angiodynamics, Navilyst, Boston Scientific, and Hitachi where he was responsible for the development and commercialization of an array of medical devices. His efforts have resulted in over 30 issued and pending patents inclusive of implantable and catheter technologies. Ray holds a B.S. and M.S. in Plastics Engineering.
VP of Quality and Regulatory
Amita has 28 years of experience in regulatory and quality for cardiovascular, neurological and implantable medical devices. She has worked for ConforMIS, Confluent Surgical, Hemasure, and CR Bard Vascular/Cardiology where she authored and successfully cleared more than 25 510ks and participated in the PMA approval process. Amita has a M.S. in Chemistry.
Director of Formulation Development
Hans Claesson has 14 years of experience in absorbable polymers and product development in medical devices from positions at TEI Bioscience, Histogenics, Smith and Nephew, and Cohesion Technologies. He developed the processing methods for Cohesion Technologies CT3® surgical sealant (next-generation CoSeal) and holds numerous patents in biomaterials.
Director of Administration
Janet has 24 years of experience in a broad range of operational roles, including procurement, HR, accounting, facilities build out and management at early stage companies and venture capital firms. Previous positions held at Focal Inc, Charles River Ventures, Reva Systems, mValent, Prism Venture Partners FirstFuel Software and Coretelligent.
Pat Campbell has over 17 years with the Incept family of companies. He started with Augmenix in 2007. Prior to Augmenix, Pat was the VP or Research and Development at Confluent Surgical. Previously Pat worked at Focal, Inc., Advanced Cardiovascular Systems, and Symbion, Inc.
Pat holds a PhD and Masters in Bioengineering, and a BS in Mechanical Engineering from the University of Utah. Pat also has over 13 issued U.S. patents.